BACKGROUND AND AIM: Anticoagulation after mitral valve repair is controversial and guidelines are not well-established. This study evaluated the association between postoperative warfarin use and complications after mitral valve repair, including bleeding and thromboembolic incidents, readmission, and mortality. METHODS: This retrospective study investigated 1097 patients who underwent elective mitral valve repair between April 2003 and March 2017, and was naïve to atrial fibrillation or prior cardiac surgery. This cohort had no other indication for or against anticoagulation. About 775 patients were placed on warfarin with international normalized ratio goal 2.5 and 322 patients were not anticoagulated. The association between anticoagulation and complications was assessed with univariate comparisons between groups and multiple logistic regression. RESULTS: Postoperative warfarin use was associated with a reduced composite of bleeding and thromboembolic complications (pulmonary embolism, TIA, stroke, pericardial effusion or cardiac tamponade, gastrointestinal bleeding, and reoperation for bleeding) with an odds ratio of 0.29 (95% confidence interval, 0.13-0.64, P = .003). There was no difference in 30-day or 6-month mortality or readmission rate between groups. Long-term survival estimates were superior in the warfarin group (10-year: 92% vs 85%; log-rank P < .001). CONCLUSIONS: Our analysis showed that postoperative warfarin use was associated with an overall reduced composite of bleeding and thromboembolic incidents and superior long-term survival. These findings suggest that anticoagulation with warfarin following mitral valve repair may be a safe and effective means for avoiding postoperative complications and that a large prospective randomized clinical trial is warranted.
BACKGROUND AND AIM: Anticoagulation after mitral valve repair is controversial and guidelines are not well-established. This study evaluated the association between postoperative warfarin use and complications after mitral valve repair, including bleeding and thromboembolic incidents, readmission, and mortality. METHODS: This retrospective study investigated 1097 patients who underwent elective mitral valve repair between April 2003 and March 2017, and was naïve to atrial fibrillation or prior cardiac surgery. This cohort had no other indication for or against anticoagulation. About 775 patients were placed on warfarin with international normalized ratio goal 2.5 and 322 patients were not anticoagulated. The association between anticoagulation and complications was assessed with univariate comparisons between groups and multiple logistic regression. RESULTS: Postoperative warfarin use was associated with a reduced composite of bleeding and thromboembolic complications (pulmonary embolism, TIA, stroke, pericardial effusion or cardiac tamponade, gastrointestinal bleeding, and reoperation for bleeding) with an odds ratio of 0.29 (95% confidence interval, 0.13-0.64, P = .003). There was no difference in 30-day or 6-month mortality or readmission rate between groups. Long-term survival estimates were superior in the warfarin group (10-year: 92% vs 85%; log-rank P < .001). CONCLUSIONS: Our analysis showed that postoperative warfarin use was associated with an overall reduced composite of bleeding and thromboembolic incidents and superior long-term survival. These findings suggest that anticoagulation with warfarin following mitral valve repair may be a safe and effective means for avoiding postoperative complications and that a large prospective randomized clinical trial is warranted.
Authors: Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce W Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Rick A Nishimura; Blase A Carabello; David P Faxon; Michael D Freed; Bruce W Lytle; Patrick T O'Gara; Robert A O'Rourke; Pravin M Shah Journal: J Am Coll Cardiol Date: 2008-09-23 Impact factor: 24.094
Authors: Nana Valeur; Charlotte Mérie; Morten Lock Hansen; Christian Torp-Pedersen; Gunnar H Gislason; Lars Kober Journal: Heart Date: 2016-01-04 Impact factor: 5.994
Authors: Thomas A Schwann; Milo Engoren; Mark Bonnell; Christopher Clancy; Samer Khouri; Ameer Kabour; Tahir Jamil; Robert H Habib Journal: Eur J Cardiothorac Surg Date: 2013-01-04 Impact factor: 4.191
Authors: Rakesh M Suri; Vinod H Thourani; Xia He; J Matthew Brennan; Sean M O'Brien; J Scott Rankin; Hartzell V Schaff; James S Gammie Journal: Ann Thorac Surg Date: 2013-06 Impact factor: 4.330
Authors: M Heras; J H Chesebro; V Fuster; W J Penny; D E Grill; K R Bailey; G K Danielson; T A Orszulak; J R Pluth; F J Puga Journal: J Am Coll Cardiol Date: 1995-04 Impact factor: 24.094
Authors: Handerson Nunes dos Santos; Ellen Hettwer Magedanz; João Carlos Vieira da Costa Guaragna; Natalia Nunes dos Santos; Luciano Cabral Albuquerque; Marco Antonio Goldani; João Batista Petracco; Luiz Carlos Bodanese Journal: Rev Bras Cir Cardiovasc Date: 2014 Apr-Jun